Cancer Market Top 20 Drugs - Supportive Care Grows the Cancer Market

Questions: Discounts, Updates etc.

Price: $15,200.00

Publication Date: 2005-01-06

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

The global cancer market is predicted to grow at a CAGR of 8%. However, a number of global and country-specific factors will support or threaten this trend including epidemiological, regulatory, legislative and pharmacoeconomic influences. Companies can mitigate the ensuing commercial risk through innovative strategies in lifecycle management and sustained R&D productivity.


Scope

  • Overview of current cancer market including profiles of the leading 20 brands by sales in 2004 and key events impacting each brand during 2004-2014
  • Assessment of current and future opportunities and threats in the cancer sector across the seven major pharmaceutical markets
  • Individual country sales for leading products are presented, with projections for future performance up to 2014
  • Detailed discussion of assumptions and events used in forecast analysis


    • Report Highlights
    The oncology market is the third largest pharmaceutical market, behind the cardiovascular and CNS therapy areas, and is currently experiencing strong growth. Worth an estimated $35 billion in 2004, Datamonitor projects the sector to grow to $60 billion by 2008, yielding a compound annual growth rate (CAGR) of 8% over this period.

    In 2004, the top 20 cancer drugs in each of the seven major pharmaceutical markets generated combined sales exceeding $27 billion, with the US accounting for 66% of this total, Japan 13% and the five EU countries 21% (Midas, IMS Health, April 2004). Collective sales in these markets represent approximately 77% of global oncology revenues.

    Over the next 10 years, Datamonitor predicts that of the cancer drugs that currently hold a top 20 position in one or more of the seven markets, only those in the innovative and supportive care classes will maintain a positive CAGR. Conversely, cytotoxics and antihormonals will experience declining sales.


    Reasons to Purchase

  • Understand market specific drivers and predict the future performance of key compounds
  • Quantify the impact of key patent expiries
  • Adopt knowledge to drive strategic planning for the lifecycle management of mature products and to optimize the market penetration of new entrants

    • Table of Contents

    Other users found this report page using the following search terms: supportive care cancer oncology antinauseants nausea vomiting antiemetics pain infection control neutropenia anemia cancer market drugs top 20 oncology patent drug sales uk

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.